Jasper Therapeutics to Present at Upcoming Conferences

Rhea-AI Summary

Jasper Therapeutics (NASDAQ: JSPR), a biotechnology firm, is focusing on innovative antibody therapies for chronic spontaneous urticaria and myelodysplastic syndromes (MDS). The company announced participation in key conferences in March 2023, including:

• William Blair’s Innovator Series on March 13, featuring CEO Ronald Martell discussing New Therapies in Urticaria.
• Oppenheimer 33rd Annual Healthcare Conference on the same day, where Martell will present the company's corporate updates.

Details for the live webcasts can be found on Jasper's Investor Events page.

REDWOOD CITY, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced that the Company will be participating in the following conferences in March.

William Blair’s Innovator Series: What’s Next in Dermatology? (Virtual)

• Ronald Martell, Chief Executive Officer, will participate in a panel discussing New Therapies in Urticaria.
  • Monday, March 13^th, 2023, at 12:00PM ET
  • Registration details available here.
    

Oppenheimer 33^rd Annual Healthcare Conference (Virtual)

• Ronald Martell, Chief Executive Officer, will give a Corporate Presentation.
  • Monday, March 13^th, 2023, at 4:00PM ET
  • Registration details available here.
    

Details for live and archived webcast will be posted at the Company’s Investor Events webpage.

About Jasper Therapeutics
Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy. For more information, please visit us at www.jaspertherapeutics.com.

Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Jasper’s priority development programs, Jasper’s resources, and its plan for achieving near-term clinical milestones. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Jasper’s product candidates; the risk that prior study results may not be replicated; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts:

John Mullaly (investors)
LifeSci Advisors
617-429-3548
jmullaly@lifesciadvisors.com

Jeet Mahal (investors)
Jasper Therapeutics
650-549-1403
jmahal@jaspertherapeutics.com

FAQ

What is Jasper Therapeutics' focus in the biotechnology sector?

Jasper Therapeutics focuses on developing novel antibody therapies targeting c-Kit (CD117) for conditions like chronic spontaneous urticaria and myelodysplastic syndromes (MDS).

When is Jasper Therapeutics participating in the William Blair Innovator Series?

Jasper Therapeutics will participate in the William Blair Innovator Series on March 13, 2023, at 12:00 PM ET.

What will Jasper Therapeutics CEO discuss at the conferences?

CEO Ronald Martell will discuss 'New Therapies in Urticaria' at the William Blair Innovator Series and give a corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference.

Where can I find details about Jasper Therapeutics' conference presentations?

Details for live and archived webcasts of Jasper Therapeutics' conference presentations can be found on their Investor Events webpage.